Preclinical evidence for the therapeutic value of TBX5 normalization in arrhythmia control
Cardiovascular Research

Abstract
Arrhythmias and sudden cardiac death (SCD) occur commonly in patients with heart failure. We found T-box 5 (TBX5) dysregulated in ventricular myocardium from heart failure patients and thus we hypothesized that TBX5 reduction contributes to arrhythmia development in these patients. To understand the underlying mechanisms, we aimed to reveal the ventricular TBX5-dependent transcriptional network and further test the therapeutic potential of TBX5 level normalization in mice with documented arrhythmias.
We used a mouse model of TBX5 conditional deletion in ventricular cardiomyocytes. Ventricular (v) TBX5 loss in mice resulted in mild cardiac dysfunction and arrhythmias and was associated with a high mortality rate (60%) due to SCD. Upon angiotensin stimulation, v
This study uncovers a novel cardioprotective role of TBX5 in the adult heart and provides preclinical evidence for the therapeutic value of TBX5 protein normalization in the control of arrhythmia.
Contributors

Franziska S Rathjens
Author

Alica Blenkle
Author

Lavanya M Iyer
Author

Anke Renger
Author

Fahima Syeda
Author

Claudia Noack
Author

Andreas Jungmann
Author

Matthias Dewenter
Author

Karl Toischer
Author

Ali El-Armouche
Author

Oliver J Müller
Author

Wolfram-Hubertus Zimmermann
Author
You may be interested in





